Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7.
Hattori F, Ohshima Y, Seki S, Tsukimoto M, Sato M, Takenouchi T, Suzuki A, Takai E, Kitani H, Harada H, Kojima S.
Hattori F, et al. Among authors: tsukimoto m.
Eur J Pharmacol. 2012 Nov 15;695(1-3):20-6. doi: 10.1016/j.ejphar.2012.09.001. Epub 2012 Sep 11.
Eur J Pharmacol. 2012.
PMID: 22981895